Rare germline variants are associated with rapid biochemical recurrence after radical prostate cancer treatment: a PPCG study

Burns, Daniel, Anokian, Ezequiel, Saunders, Edward J., Bristow, Robert G., Fraser, Michael, Reimand, Jüri, Schlomm, Thorsten, Sauter, Guido, Brors, Benedikt, Korbel, Jan, Weischenfeldt, Joachim, Waszak, Sebastian M., Corcoran, Niall M., Jung, Chol-Hee, Pope, Bernard J., Hovens, Chris M., Cancel-Tassin, Géraldine, Cussenot, Olivier, Loda, Massimo, Sander, Chris, Hayes, Vanessa M., Dalsgaard Sorensen, Karina, Lu, Yong-Jie, Hamdy, Freddie C., Foster, Christopher S., Gnanapragasam, Vincent, Butler, Adam, Lynch, Andy G., Massie, Charlie E., Woodcock, Dan J., Cooper, Colin S. ORCID: https://orcid.org/0000-0003-2013-8042, Wedge, David C., Brewer, Daniel S. ORCID: https://orcid.org/0000-0003-4753-9794, Kote-Jarai, Zsofia and Eeles, Rosalind A. and CR-UK/Prostate Cancer UK, ICGC, The PPCG (2022) Rare germline variants are associated with rapid biochemical recurrence after radical prostate cancer treatment: a PPCG study. European Urology, 82 (2). pp. 201-211. ISSN 0302-2838

[thumbnail of Revised_Manuscript_table_precision_amended]
Preview
PDF (Revised_Manuscript_table_precision_amended) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (444kB) | Preview
[thumbnail of Supplementary]
Preview
PDF (Supplementary) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (420kB) | Preview

Abstract

Background: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression.  Objective: To find rare germline variants that predict time to biochemical recurrence (BCR) after radical treatment in men with PrCa, and understand the genetic factors associated with such progression.  Design, Setting and Participants: Whole-genome sequencing data from blood DNA were analysed for 850 PrCa patients with radical treatment from the Pan Prostate Cancer Group (PPCG consortium) from UK, Canada, Germany, Australia and France. Findings were validated using 383 patients from The Cancer Genome Atlas (TCGA).  Outcome Measurements and Statistical analysis: 15,822 rare (MAF<1%) predicted-deleterious coding germline mutations were identified. Optimal multifactor and univariate Cox regression models were built to predict time to BCR after radical treatment, using germline variants grouped by functionally annotated gene-sets. Models were tested for robustness using bootstrap resampling.  Results: Optimal Cox regression multifactor models showed that rare predicted-deleterious germline variants in “Hallmark” gene-sets were consistently associated with altered time to BCR. Three gene-sets had a statistically significant association with risk-elevated outcome when modelling all samples: PI3K/AKT/mTOR, Inflammatory response and KRAS signalling (up). PI3K/AKT/mTOR and KRAS signalling (up) were also associated among patients with higher grade cancer, as were Pancreas-beta cells, TNFA signalling via NKFB and Hypoxia, the latter of which was validated in the independent TCGA dataset.  Conclusions: We demonstrate for the first time that rare deleterious coding germline variants robustly associate with time to BCR after radical treatment, including cohort-independent validation. Our findings suggest that germline testing at diagnosis could aid clinical decisions by stratifying patients for differential clinical management.  Patient summary: PrCa patients with particular genetic mutations have a higher chance of relapsing after initial radical treatment, potentially providing opportunities to identify which patients might need additional treatments earlier.

Item Type: Article
Uncontrolled Keywords: biochemical recurrence,germline variants,pan prostate cancer group,prostate cancer,urology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2748
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 01 Jun 2022 13:30
Last Modified: 19 Oct 2023 03:20
URI: https://ueaeprints.uea.ac.uk/id/eprint/85286
DOI: 10.1016/j.eururo.2022.05.007

Actions (login required)

View Item View Item